Vicore Pharma Holding AB

NASDAQ:VCRE

Medical - Pharmaceuticals

Healthcare
$9.90 -1.66%

-$0.24 today

Market cap
$279.65M
Beta
0.15

Volume 0.00M

Average 0.26M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$375.74M

FY 2025 · Annual

Investing Cash Flow

-$600.51M

FY 2025 · Annual

Financing Cash Flow

$430.54M

FY 2025 · Annual

-48.4% YoY

Cash Flow Statement

SEK
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(32.78M)(290.73M)(321.51M)(194.19M)(452.39M)
Depreciation & Amortization397.75K3.61M3.42M2.24M0
Deferred Income Tax00000
Stock-Based Compensation(172.79K)0000
Change in Working Capital(37.59K)(20.94M)(10.65M)(1.84M)40.81M
Accounts Receivables(37.59K)(1.6M)(4.28M)(35.6M)(3.08M)
Inventory00000
Accounts Payables00000
Other Working Capital0(19.34M)(6.36M)33.77M43.89M
Other Non-Cash Items(231.23M)8.13M79.15M28.84M35.84M
Operating Cash Flow(263.82M)(299.92M)(249.58M)(164.95M)(375.74M)
Capital Expenditures0(3M)000
Acquisitions (Net)00000
Purchases of Investments(76.61M)0(199.04M)(64.81M)(983.95M)
Sales of Investments69.64M77M54.58M213.85M383.45M
Other Investing Activities00000
Investing Cash Flow(6.96M)74M(144.46M)149.04M(600.51M)
Debt Repayment00000
Common Stock Issued316.8M200M500.41M882.14M455.1M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(237.78K)(12.96M)(29.55M)(48.08M)(24.55M)
Financing Cash Flow316.56M187.04M470.86M834.06M430.54M
Effect of Forex Changes(26.64M)1.48M04.23M(32.16M)
Net Change in Cash2.3M(37.4M)76.82M822.38M(577.85M)
Free Cash Flow(263.82M)(302.92M)(249.58M)(164.95M)(375.74M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$452.4M
+ D&A$0
+ Stock-Based Comp$0
+ Deferred Tax$0
+ Working Capital$40.8M
+ Other Non-Cash$35.8M
= Operating Cash Flow-$375.7M
- Capex$0
= Free Cash Flow-$375.7M

Analysis

FY2025 free cash flow is -$375.7M. FCF conversion is 83.1% of net income. Operating cash flow was -$375.7M, with capex of $0. The largest bridge item is Working Capital at $40.8M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
6-K6-K filingNov 5, 2026
6-K6-K filingNov 3, 2026
6-K6-K filingOct 22, 2026
SC 13GSC 13G filingOct 13, 2026
6-K6-K filingSep 30, 2026

Does VCRE generate free cash flow?

Vicore Pharma Holding AB (VCRE) generated -$375.74M of free cash flow in fiscal 2025.

How much operating cash flow does VCRE produce?

Operating cash flow was -$375.74M, before capital expenditures of $0.00.